ADCs forecast to capture $3.9 billion NSCLC market by 2032

27 May 2025

The market for antibody-drug conjugates (ADCs) in non-small cell lung cancer (NSCLC) is poised for significant growth, projected to surpass $3.9 billion by 2032 across the USA, Europe, and Japan, according to data and analytics group GlobalData.

This expansion follows a prolonged period of limited ADC presence in NSCLC. Although the American medicines regulator approved Pfizer’s (NYSE: PFE) Mylotarg (gemtuzumab ozogamicin) in 2000, it wasn't until 2022 that the first ADC for NSCLC—AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab deruxtecan)—received approval, targeting HER2-mutated tumors.

Since then, the development pipeline has accelerated. GlobalData anticipates a compound annual growth rate of 6.8% for ADCs in NSCLC across the seven major markets—USA, France, Germany, Italy, Spain, the UK, and Japan—driven by late-stage candidates nearing approval.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology